Evidence of activity of Irinotecan in patients with advanced AIDS-related Kaposi's sarcoma

Emanuela Vaccher, Giampiero Di Gennaro, Cecilia Simonelli, Ornella Schioppa, Umberto Tirelli

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Fourteen HIV-infected patients with advanced Kaposi's sarcoma (KS) received Irinotecan 150 mg/m2 intravenously on days 1 and 10. All patients were relapsed/progressed during highly active antiretroviral therapy, administered as primary antineoplastic therapy. An objective response, all partial remissions, occurred in 75% of patients. Irinotecan was well tolerated, severe leukopenia occurred in only 33% of patients. In HIV-infected patients with advanced KS, irinotecan is active and well tolerated.

Original languageEnglish
Pages (from-to)1915-1916
Number of pages2
JournalAIDS (London, England)
Volume19
Issue number16
Publication statusPublished - Nov 4 2005

Fingerprint

irinotecan
Kaposi's Sarcoma
HIV
Highly Active Antiretroviral Therapy
Leukopenia
Antineoplastic Agents
AIDS-related Kaposi sarcoma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Vaccher, E., Di Gennaro, G., Simonelli, C., Schioppa, O., & Tirelli, U. (2005). Evidence of activity of Irinotecan in patients with advanced AIDS-related Kaposi's sarcoma. AIDS (London, England), 19(16), 1915-1916.

Evidence of activity of Irinotecan in patients with advanced AIDS-related Kaposi's sarcoma. / Vaccher, Emanuela; Di Gennaro, Giampiero; Simonelli, Cecilia; Schioppa, Ornella; Tirelli, Umberto.

In: AIDS (London, England), Vol. 19, No. 16, 04.11.2005, p. 1915-1916.

Research output: Contribution to journalArticle

Vaccher, E, Di Gennaro, G, Simonelli, C, Schioppa, O & Tirelli, U 2005, 'Evidence of activity of Irinotecan in patients with advanced AIDS-related Kaposi's sarcoma', AIDS (London, England), vol. 19, no. 16, pp. 1915-1916.
Vaccher E, Di Gennaro G, Simonelli C, Schioppa O, Tirelli U. Evidence of activity of Irinotecan in patients with advanced AIDS-related Kaposi's sarcoma. AIDS (London, England). 2005 Nov 4;19(16):1915-1916.
Vaccher, Emanuela ; Di Gennaro, Giampiero ; Simonelli, Cecilia ; Schioppa, Ornella ; Tirelli, Umberto. / Evidence of activity of Irinotecan in patients with advanced AIDS-related Kaposi's sarcoma. In: AIDS (London, England). 2005 ; Vol. 19, No. 16. pp. 1915-1916.
@article{dcdd1a569c424383a469c1da5989c429,
title = "Evidence of activity of Irinotecan in patients with advanced AIDS-related Kaposi's sarcoma",
abstract = "Fourteen HIV-infected patients with advanced Kaposi's sarcoma (KS) received Irinotecan 150 mg/m2 intravenously on days 1 and 10. All patients were relapsed/progressed during highly active antiretroviral therapy, administered as primary antineoplastic therapy. An objective response, all partial remissions, occurred in 75{\%} of patients. Irinotecan was well tolerated, severe leukopenia occurred in only 33{\%} of patients. In HIV-infected patients with advanced KS, irinotecan is active and well tolerated.",
author = "Emanuela Vaccher and {Di Gennaro}, Giampiero and Cecilia Simonelli and Ornella Schioppa and Umberto Tirelli",
year = "2005",
month = "11",
day = "4",
language = "English",
volume = "19",
pages = "1915--1916",
journal = "AIDS",
issn = "0269-9370",
publisher = "NLM (Medline)",
number = "16",

}

TY - JOUR

T1 - Evidence of activity of Irinotecan in patients with advanced AIDS-related Kaposi's sarcoma

AU - Vaccher, Emanuela

AU - Di Gennaro, Giampiero

AU - Simonelli, Cecilia

AU - Schioppa, Ornella

AU - Tirelli, Umberto

PY - 2005/11/4

Y1 - 2005/11/4

N2 - Fourteen HIV-infected patients with advanced Kaposi's sarcoma (KS) received Irinotecan 150 mg/m2 intravenously on days 1 and 10. All patients were relapsed/progressed during highly active antiretroviral therapy, administered as primary antineoplastic therapy. An objective response, all partial remissions, occurred in 75% of patients. Irinotecan was well tolerated, severe leukopenia occurred in only 33% of patients. In HIV-infected patients with advanced KS, irinotecan is active and well tolerated.

AB - Fourteen HIV-infected patients with advanced Kaposi's sarcoma (KS) received Irinotecan 150 mg/m2 intravenously on days 1 and 10. All patients were relapsed/progressed during highly active antiretroviral therapy, administered as primary antineoplastic therapy. An objective response, all partial remissions, occurred in 75% of patients. Irinotecan was well tolerated, severe leukopenia occurred in only 33% of patients. In HIV-infected patients with advanced KS, irinotecan is active and well tolerated.

UR - http://www.scopus.com/inward/record.url?scp=27544497964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27544497964&partnerID=8YFLogxK

M3 - Article

C2 - 16227802

AN - SCOPUS:27544497964

VL - 19

SP - 1915

EP - 1916

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 16

ER -